Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Haemonetics (HAE) EBITDA Margin (2016 - 2025)

Haemonetics has reported EBITDA Margin over the past 17 years, most recently at 19.88% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 1513.0% year-over-year to 19.88%; the TTM value through Dec 2025 reached 19.05%, up 1033.0%, while the annual FY2025 figure was 16.3%, 370.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 19.88% at Haemonetics, up from 17.87% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 21.58% in Q1 2025 and troughed at 9.41% in Q2 2021.
  • A 5-year average of 9.58% and a median of 9.17% in 2022 define the central range for EBITDA Margin.
  • Biggest five-year swings in EBITDA Margin: plummeted -2031bps in 2021 and later skyrocketed 1665bps in 2022.
  • Year by year, EBITDA Margin stood at 6.01% in 2021, then surged by 104bps to 12.25% in 2022, then dropped by -4bps to 11.77% in 2023, then plummeted by -60bps to 4.75% in 2024, then soared by 319bps to 19.88% in 2025.
  • Business Quant data shows EBITDA Margin for HAE at 19.88% in Q4 2025, 17.87% in Q3 2025, and 16.76% in Q2 2025.